1. Characteristics

2. How does S€max work?

S€max engages the brain through several converging pathways. Upregulation of BDNF and nerve growth factor (NGF) supports neuronal survival, structural growth, and synaptic plasticity, while concurrent enhancement of serotonergic and dopaminergic activity influences mood, motivation, and higher cognitive functions. At the cellular level, antioxidant and anti-inflammatory activity shields neurons from oxidative and inflammation-related damage. Research has also identified an inhibitory effect on beta-amyloid peptide accumulation, relevant to neurodegeneration research, alongside improvements in cerebral circulation that enhance oxygen and nutrient availability to neural tissue.

3. Research Findings

• Cognitive Enhancement: Memory, learning capacity, and attentional performance have shown improvement across animal models and clinical investigations, with effects documented in both healthy subjects and those presenting with cognitive impairment.
• Neuroprotection: Neuronal survival under conditions including ischemia, traumatic injury, and neurodegenerative pathology has been supported by S€max activity, reflecting its broad cytoprotective profile.
• Mood Regulation: Serotonergic and dopaminergic modulation positions S€max as a subject of investigation for anxiolytic and antidepressant-relevant effects in experimental settings.
• Stroke Recovery: Functional recovery and reduction of neurological deficits following ischemic stroke have been observed in animal models, with supporting data from clinical research in stroke patient populations.
• Neurodegenerative Disorders: Its combined neuroprotective and cognitive-enhancing properties have prompted investigation into Alzheimer's and Parkinson's disease contexts, particularly regarding beta-amyloid dynamics and neurotrophic factor regulation.

4. Side Effects

S€max demonstrates a favorable tolerability profile in clinical research. Reported adverse effects remain limited to headache, dizziness, and occasional allergic reactions in sensitive individuals.

5. Summary

S€max occupies a distinctive position among neuropeptides under investigation, engaging neurotrophic, neurotransmitter, vascular, and inflammatory systems in parallel. The convergence of these mechanisms across cognitive, protective, and mood-related domains makes it a valuable research instrument for studying complex neurological processes and evaluating potential intervention strategies for conditions ranging from acute ischemic injury to chronic neurodegeneration.

6. References

• 1. Dolotov OV et al. Brain Research, 2006. S€max, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. PubMed 16635254
• 2. Medvedeva EV et al. Molecular Genetics and Genomics, 2017. S€max, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats. PubMed 28255762
• 3. Gusev EI et al. Zhurnal Nevrologii i Psikhiatrii, 2018. The efficacy of S€max in the treatment of patients at different stages of ischemic stroke. PubMed 29798983
• 4. Lebedeva IS et al. Bulletin of Experimental Biology and Medicine, 2018. Effects of S€max on the Default Mode Network of the Brain. PubMed 30225715
• 5. Dmitrieva VG et al. Cellular and Molecular Neurobiology, 2010. S€max and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. PubMed 19633950
• 6. Medvedeva EV et al. BMC Genomics, 2014. The peptide S€max affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia. PubMed 24661604

7. Research use